Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Precision BioSciences (DTIL – Research Report). The associated price target remains the same with $30.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Soumit Roy has given his Buy rating due to a combination of factors surrounding Precision BioSciences’ promising developments and strategic decisions. The company is on the cusp of significant milestones in 2025, particularly with its lead program PBGENE-HBV for chronic Hepatitis B. The ongoing Phase 1 trial is expected to yield multiple updates throughout the year, with the potential to present findings at major conferences, which could enhance the company’s visibility and credibility in the healthcare sector.
Additionally, Precision BioSciences is making strategic decisions regarding its PBGENE-DMD program for Duchenne Muscular Dystrophy. The company is exploring options to either partner or fully develop this program, leveraging their ARCUS technology to address significant genetic mutations. These advancements, coupled with the company’s financial positioning and potential for strategic partnerships, underpin the Buy rating as they suggest a promising future for Precision BioSciences.
Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Elicio Therapeutics, and Chimerix. According to TipRanks, Roy has an average return of -27.6% and a 15.15% success rate on recommended stocks.
In another report released on March 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.